Corinne Johnson
Stock Analyst at Goldman Sachs
(3.12)
# 1,409
Out of 5,182 analysts
16
Total ratings
53.33%
Success rate
14.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $28 → $34 | $24.64 | +37.99% | 3 | Apr 1, 2026 | |
| TGTX TG Therapeutics | Maintains: Neutral | $37 → $39 | $33.39 | +16.80% | 1 | Jan 15, 2026 | |
| IMVT Immunovant | Maintains: Neutral | $18 → $28 | $24.61 | +13.77% | 2 | Dec 15, 2025 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $30.19 | -40.38% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $16.27 | +22.93% | 2 | Sep 16, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $25.19 | +31.00% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $130.90 | +39.04% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $69.81 | -28.38% | 3 | May 14, 2024 |
Syndax Pharmaceuticals
Apr 1, 2026
Maintains: Buy
Price Target: $28 → $34
Current: $24.64
Upside: +37.99%
TG Therapeutics
Jan 15, 2026
Maintains: Neutral
Price Target: $37 → $39
Current: $33.39
Upside: +16.80%
Immunovant
Dec 15, 2025
Maintains: Neutral
Price Target: $18 → $28
Current: $24.61
Upside: +13.77%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $30.19
Upside: -40.38%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $16.27
Upside: +22.93%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $25.19
Upside: +31.00%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $130.90
Upside: +39.04%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $69.81
Upside: -28.38%